Skip to content

Tap Block and Cesarean Delivery: Efficacy and Consumption of Postoperative Drugs

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02801968
Acronym
TAPFANS
Enrollment
62
Registered
2016-06-16
Start date
2016-04-30
Completion date
2016-09-30
Last updated
2016-06-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cesarean Delivery

Brief summary

The purpose of this study is to determine the efficacy of Tap block after cesarean delivery as a component of multimodal analgesia and evaluation of postoperative drugs consumption.

Interventions

PROCEDURETap block

Sponsors

S. Anna Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* age \> 18 years * written consent * anesthesiologist's assent on preoperative evaluation

Exclusion criteria

* age\< 18 years * uncooperative patients * written consent not obtained * local anesthetic allergy * BMI \> 35

Design outcomes

Primary

MeasureTime frameDescription
Pain evaluation with Numerical Rating Scale (NRS)Pain evaluation with NRS at 2,6,12,24 hours after cesarean delivery in TAP block group and in the control group.We don't want to measure the change between each assessment within a single group, instead we want considering the difference in the measurements between two separate groups (TAP block group and control group) for each time point.

Secondary

MeasureTime frame
Evaluation of NSAIDs (nonsteroidal anti-inflammatory drugs) consumption as rescue dose during the first 24 hours after cesarean deliveryDoses of NSAIDs (nonsteroidal anti-inflammatory drugs) administered at 2, 6, 12 ,24 hours after cesarean delivery TAP block group and in the control group.

Countries

Italy

Contacts

Primary ContactIlaria Farinelli
ilaria.farinelli@unife.it+393332082120

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026